|
|
Line 3: |
Line 3: |
| <StructureSection load='3u4h' size='340' side='right'caption='[[3u4h]], [[Resolution|resolution]] 1.88Å' scene=''> | | <StructureSection load='3u4h' size='340' side='right'caption='[[3u4h]], [[Resolution|resolution]] 1.88Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[3u4h]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3U4H OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3U4H FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[3u4h]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3U4H OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3U4H FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=C8R:8-AMINO-N1-CYCLIC+INOSINE+5-DIPHOSPHORIBOSE'>C8R</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.878Å</td></tr> |
- | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[3u4i|3u4i]]</div></td></tr>
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=C8R:8-AMINO-N1-CYCLIC+INOSINE+5-DIPHOSPHORIBOSE'>C8R</scene></td></tr> |
- | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CD38 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | + | |
- | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/NAD(+)_nucleosidase NAD(+) nucleosidase], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.2.2.5 3.2.2.5] </span></td></tr>
| + | |
| <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3u4h FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3u4h OCA], [https://pdbe.org/3u4h PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3u4h RCSB], [https://www.ebi.ac.uk/pdbsum/3u4h PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3u4h ProSAT]</span></td></tr> | | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3u4h FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3u4h OCA], [https://pdbe.org/3u4h PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3u4h RCSB], [https://www.ebi.ac.uk/pdbsum/3u4h PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3u4h ProSAT]</span></td></tr> |
| </table> | | </table> |
| == Function == | | == Function == |
- | [[https://www.uniprot.org/uniprot/CD38_HUMAN CD38_HUMAN]] Synthesizes cyclic ADP-ribose, a second messenger for glucose-induced insulin secretion. Also has cADPr hydrolase activity. Also moonlights as a receptor in cells of the immune system.
| + | [https://www.uniprot.org/uniprot/CD38_HUMAN CD38_HUMAN] Synthesizes cyclic ADP-ribose, a second messenger for glucose-induced insulin secretion. Also has cADPr hydrolase activity. Also moonlights as a receptor in cells of the immune system. |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
Line 28: |
Line 26: |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
- | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| [[Category: Large Structures]] | | [[Category: Large Structures]] |
- | [[Category: Graeff, R]] | + | [[Category: Graeff R]] |
- | [[Category: Hao, Q]] | + | [[Category: Hao Q]] |
- | [[Category: Lee, H C]] | + | [[Category: Lee HC]] |
- | [[Category: Liu, Q]] | + | [[Category: Liu Q]] |
- | [[Category: 8-amino-n1-cidpr]]
| + | |
- | [[Category: Cadpr cyclization]]
| + | |
- | [[Category: Hydrolase-hydrolase inhibitor complex]]
| + | |
- | [[Category: Hydrolysis]]
| + | |
- | [[Category: Non-hydrolyzable inhibitor]]
| + | |
- | [[Category: Two domain]]
| + | |
| Structural highlights
Function
CD38_HUMAN Synthesizes cyclic ADP-ribose, a second messenger for glucose-induced insulin secretion. Also has cADPr hydrolase activity. Also moonlights as a receptor in cells of the immune system.
Publication Abstract from PubMed
Few inhibitors exist for CD38, a multifunctional enzyme catalyzing the formation and metabolism of the Ca2+-mobilizing second messenger cyclic adenosine 5'-diphosphoribose (cADPR). Synthetic, non-hydrolyzable ligands can facilitate structure-based inhibitor design. Molecular docking was used to reproduce the crystallographic binding mode of cyclic inosine 5'-diphosphoribose (N1-cIDPR) with CD38, revealing an exploitable pocket and predicting the potential to introduce an extra hydrogen bond interaction with Asp-155. The purine C-8 position of N1-cIDPR (IC50 276 microM) was extended with an amino or diaminobutane group and the 8-modified compounds were evaluated against CD38-catalyzed cADPR hydrolysis. Crystallography of an 8-amino N1-cIDPR:CD38 complex confirmed the predicted interaction with Asp-155, together with a second H-bond from a realigned Glu-146, rationalizing the improved inhibition (IC50 56 microM). Crystallography of a complex of cyclic ADP-carbocyclic ribose (cADPcR, IC50 129 microM) with CD38 illustrated that Glu-146 hydrogen bonds with the ligand N6-amino group. Both 8-amino N1-cIDPR and cADPcR bind deep in the active site reaching the catalytic residue Glu-226, and mimicking the likely location of cADPR during catalysis. Substantial overlap of the N1-cIDPR "northern" ribose monophosphate and the cADPcR carbocyclic ribose monophosphate regions suggests that this area is crucial for inhibitor design, leading to a new compound series of N1-inosine 5'-monophosphates (N1-IMPs). These small fragments inhibit hydrolysis of cADPR more efficiently than the parent cyclic compounds, with the best in the series demonstrating potent inhibition (IC50 = 7.6 microM). The lower molecular weight and relative simplicity of these compounds compared to cADPR make them attractive as a starting point for further inhibitor design.
CD38 Structure-Based Inhibitor Design Using the 1-Cyclic Inosine 5'-Diphosphate Ribose Template.,Moreau C, Liu Q, Graeff R, Wagner GK, Thomas MP, Swarbrick JM, Shuto S, Lee HC, Hao Q, Potter BV PLoS One. 2013 Jun 19;8(6):e66247. Print 2013. PMID:23840430[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Moreau C, Liu Q, Graeff R, Wagner GK, Thomas MP, Swarbrick JM, Shuto S, Lee HC, Hao Q, Potter BV. CD38 Structure-Based Inhibitor Design Using the 1-Cyclic Inosine 5'-Diphosphate Ribose Template. PLoS One. 2013 Jun 19;8(6):e66247. Print 2013. PMID:23840430 doi:10.1371/journal.pone.0066247
|